Your SlideShare is downloading. ×
0
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
M100700053 shivani kakria
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

M100700053 shivani kakria

910

Published on

MARKETING MANAGEMENT ASSIGNMENT

MARKETING MANAGEMENT ASSIGNMENT

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
910
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
10
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Presentation <br />On<br />NOVARTIS<br />(A PHARMACEUTICAL<br />COMPANY)<br />SHIVANI KAKRIA<br />
  • 2.
  • 3.
  • 4. SLOGAN OF NOVARTIS<br />CARING AND CURING<br />
  • 5. MISSION<br />INNOVATION IS THE ESSENCE MISSION OF NOVARTIS.<br />
  • 6. VISSION<br /><ul><li>HEALTHCARE THAT FOCUSES ON CREATING,DEVELOPING AND MANUFACTURING A WIDE RANGEOFCOMPETITIVELY DIFFERENTIATED PRODUCTSTHAT RESTORE,MAINTAIN AND IMPROVE THE HEALTH AND WELL-BEING OF CUSTOMERS.</li></li></ul><li>HEADQUARTER IN BASEL<br />
  • 7. HUMAN RESOURCE <br />BUILDING OF NOVARTIS<br />IN BASEL.<br />
  • 8. KEY PEOPLE<br />CHAIRMAN : DANIEL VASELLA<br />CEO: JOSEPH JIMENEZ<br />
  • 9. <ul><li>REVENUE:US $44.27BILLION
  • 10. NETINCOME:US$8.40BILLION
  • 11. OPERATING INCOME:US $9.98
  • 12. EMPLOYEES:99,830
  • 13. SUBSIDIARIES:CIBAVISION,SANDOZ</li></li></ul><li>NOVARTIS WINS TWO<br /> SCRIP AWARDS FOR <br />BEST OVERALL PIPELINE<br />AND CORPORATE SOCIAL <br />RESPONSIBILITY.<br />
  • 14.
  • 15. SHARE ANALYSIS OF NOVARTIS<br />
  • 16. GROWTH IN VARIOUS PRODUCT CATEGORIES…..<br />
  • 17. EMERGING MARKETS<br />OF NOVARTIS<br /><ul><li>CHINA
  • 18. RUSSIA
  • 19. TURKEY
  • 20. SOUTH KOREA
  • 21. BRAZIL
  • 22. INDIA</li></li></ul><li>
  • 23. EMERGING MARKKETS IN PHARMACEUTICALS..<br />
  • 24. SOME IMP. FACTS<br /><ul><li>WE OFFER A BROAD RANGE OF HEALTHCARE SOLUTIONS THAT MEETS</li></ul>THE EVOLVING AND UNMET NEEDS OF PATIENTS AND SOCITIES<br />WORLDWIDE.<br /><ul><li>OUR MEDICINES AND VACCINES PROTECTED 930 MILLION</li></ul>PEOPLE IN 2009.<br /><ul><li>STRONG FINANCIAL PERFORMANCE SHOWS OUR ABILITY TO</li></ul>TO FULFILL OUR PRIMARY MISSIONTO CARE AND CURE..<br /><ul><li>WHERE INTEGERITY AND HIGH ETHICAL STANDARDS REMAINS</li></ul>ESSENTIAL TO OUR LONG TERM SUCCESS. <br />
  • 25. ABOUT COMPANY<br /><ul><li>A PHARMACEUTICAL COMPANY
  • 26. FOUNDED IN 1996,
  • 27. HD.QT’S-BASEL AND SWITZERLAND.
  • 28. RANKING 3 IN SALES AMONG</li></ul> WORLDWIDE INDUSTRY.<br /><ul><li>IS 6TH LARGEST IN TERMS OF REVENUE..
  • 29. IS MEMBER OF EUROPEAN FEDERATION OF</li></ul>PHARMACEUTICAL INDUSTRIES ANDASSOCIATION.<br />
  • 30. NOVERTIS PRODUCTS<br />
  • 31. USD FIXED INCOME SECURITIES<br />
  • 32. FINANCIAL DEVELOPMENTS IN<br />2009<br />NET SALES:RISE 7%(+11% IN LOCAL CURRENCY TO USD 44.3BILLION.<br />PHARMACEUTICALS: RANKS AS ONE OF THE INDUSTRY FAST GROWING COMPANIES IN 2009 WITH NET SALES OF 8%(+12% IN LC) TO USD 28.5BILLION.<br />VACCINES AND DIAGNOSTICS:38%(39% IN LC) NET SALES INCCREASE TO USD 2.4 BILLION..<br />SANDOZ: NET SALES FALLS 1% TO USD 7.5 BILLION BUT RISE 5%LC AS NEGATIVE CURRENCY OVERSHADOWS OPERATIONAL GAINS FROM NEW LAUNCHES.<br />CONSUMER HEALTH:EXPAND MARKET SHARE IN ALL BUSINESS ECONOMIC ACTIVITIES WITH SALES OF USD 5.8 BILLION.<br />;<br />
  • 33. SOME OTHER FINANCIAL<br />DEVELOPMENTS<br />OPERATING INCOME:ADVANCES 11% TO USD 10.0 BILLION ON THE SOLID BUSINESS EXPANSIONAND PRODUCTIVITY GAINS MORE DUE TO NEGATIVE IMPACT OF LOCAL CURRENCY.<br />NET INCOME:GROWS 4% TO USD 8.5 BILLION DUE TO RELATED FINANCIAL COST AND INCOME FROM ASSOCIATED COMPANIES.<br />BASIC EARNING PER SHARE:RISE FROM 3% TO 3.70,CORE EPS RISES FROM 8% TO USD 4.50.<br />DIVIDEND:INCREASES 3.7%<br />PRODUCTIVITY:EXCEEDING THE TARGET BY 0.7 BILLION.<br />
  • 34. WHAT TYPE OF BUSINESS WE ARE IN??<br /><ul><li>PHARMACEUTICAL
  • 35. VACCINES AND DIAGNOSTICS
  • 36. SANDOZ(GENERICS)
  • 37. OVER THE COUNTER
  • 38. ANIMAL HEALTH
  • 39. CIBA VISION</li></li></ul><li>Comtan- $420 M (2007)- Parkinson's disease<br />Diovan- $5.0 B sales[25] (2007)- Hypertension<br />Exjade- $357 M (2007) - Ironchelator<br />Femara- $937 M (2007)- Breast cancer<br />Gleevec- $3.1 B- for Chronic myeloid leukemia<br />Lescol- $665 M (2007)- hypercholesterolemia<br />Lotrel- $748 M (2007)- Hypertension<br />Lucentis- $393 M (2007)- Age-related macular degeneration<br />Ritalin- $375 M (2007) - AD/HD<br />Exelon- $632 M (2007)- Alzheimer's disease<br />Sandimmune and Neoral- $944 M (2007)- Organ transplantation<br />Sandostatin - $1.0 B (2007) - Acromegaly<br />Tegretol- $413 M (2007)- Epilepsy<br />Termalgin - (Paracetamol and compounds.) - Treatment of fever and light pain.<br />Tobramycin- $273 M (2007)- Cystic fibrosis<br />Trileptal- $692 M (2007)- Epilepsy<br />Voltaren- $747 M (2007)- anti-inflammatory<br />Zometa- $1.3 B (2007)- Cancer complications<br />Tofranil- - antidepressant<br />PHARMACEUTICALS<br />
  • 40. HEALTHCARE OTC<br />Benefiber<br />Buckley's cold and cough formula<br />Bufferin<br />Comtrex cold and cough<br />Denavir/Vectavir<br />Desenex<br />Doan's pain relief<br />Ex-Lax<br />Excedrin<br />Fenistil<br />Gas-X<br />Habitrol<br />Keri skin care<br />Lamisil foot care<br />Lipactin Herpes symptomatic treatment<br />Maalox<br />Nicotinell<br />No-doz<br />
  • 41. ANIMAL CARE<br /><ul><li>PETS CARE</li></ul>Interceptor (Milbemycin oxime), oral worm control product<br />Sentinel Flavor Tabs (Milbemycin oxime, Lufenuron), oral flea control product<br />Deramaxx (Deracoxib), oral treatment for pain and inflammation from osteoarthritis in dogs<br />Caps tar (Nitenpyram), oral tablet for flea control<br />Milbemax (Milbemycin oxime, Praziquantel), oral worm treatment<br />Program (Lufenuron), oral tablet for flea control<br /><ul><li>LIVESTOCK</li></ul>Acatalk Duostar (Fluazuron, Ivermectin), tick control for cattle<br />CLiK (Dicyclanil), blowfly control for sheep<br />Denagard (Tiamulin)<br />Fasinex (Triclabendazole)<br />ViraShield<br />
  • 42. NET SALES BY REGION IN %<br />
  • 43. CORE OPERATING INCOME <br />BY DIVISION IN %<br />
  • 44. NET SALES BY DIVISION IN %<br />
  • 45. COMPETITORS IN INDIA<br />NAME OF THE COUNTRY<br />DR.REDDY’S LAB<br />CIPLA<br />PIRAMAL HEALTHCARE<br />GLAXO INDIA LTD.<br />SUN PHARMACEUTICAL<br />TOTAL REVENUE<br /> (IN USD BILLIONS)<br />1.5 <br />1.28<br />0.84<br />0.43<br />0.42<br />
  • 46. COMPETITORS IN SWITZERLAND<br />TOTAL REVENUE<br /> (IN USD BILLIONS)<br />47.35<br />4.26<br />NAME OF THE COUNTRY<br />HOFFMAN LA ROCHE<br />2.NYCOMED<br />
  • 47. COMPETITORS IN GERMANY<br />NAME OF THE COUNTRY<br />BAYER<br />BOEHRINGER INGELHEIM<br />MERCK kGaA<br />TOTAL REVENUE<br /> (IN USD BILLIONS)<br />22.3<br />16.9<br />5.17<br />
  • 48. COMPETITORS IN JAPAN<br />NAME OF THE COUNTRY<br />TAKEDAPHARMACEUTICAL.<br />ASTELLAS PHARMA<br />DAIICHI SANKYO 9<br />EISAI<br />CHUGAI PHARMACEUTICAL .<br />TOTAL REVENUE<br /> (IN USD BILLIONS)<br />15.6<br />10.7<br />9<br />5.5<br />2.0<br />
  • 49. COMPETITORS IN USA<br />TOTAL REVENUE(IN USD BILLIONS )<br />61.90<br />30.76 <br /> 27.43 <br />21.84<br />18.81<br />NAME OF THE COMPANY<br />JOHNSON AND JOHNSON<br />ABOTT LABORATORIES<br />MERC K AND CO.<br />ELI LILLY<br />BRISTOL MAYER SQUIBB<br />
  • 50. COMPETITORS IN UK<br />NAMEOF THE COMPANY<br />TOTAL REVENUE<br /> (IN USD BILLIONS)<br />45.83<br /> 32.81<br />GlaxoSmithKline<br />AstraZeneca<br />
  • 51.
  • 52.
  • 53.
  • 54. 2009 net sales - USD 7.5 billion<br />                                                                                                                                                     <br />DIOVAN<br />
  • 55. CHEMICAL DATA<br /><ul><li>FORMULA:C24H29N5O3
  • 56. MOL.MAS:435.519G/MOL
  • 57. SMILES:eMolecules AND Pubchem</li></li></ul><li>Pharmacokinetic data<br /><ul><li>Bioavailability:25%
  • 58. Protein binding:95%
  • 59. Half life :6hours
  • 60. Excretion:renal 30%,biliary70%</li></li></ul><li>DIOVAN IS INDICATED<br />FOR THE TREATMENT <br />OF<br /><ul><li> HIGH BLOOD PRESSURE,
  • 61. HEART FAILURE AND
  • 62. MYOCARDIAL INFARCTION.</li></li></ul><li>FOR THE DIABETES PATIENTS<br />In patients with impaired glucose tolerance, valsartan may decrease the incidence of developing type 2 diabetes mellitus. However, the absolute risk reduction is small (<1%/year) and diet + exercise or other drugs, maybe more protective. In the same study, no reduction in the rate of cardiovascular events (including death) was shown. In other words, taking Valsartan didn't make the patients live longer.<br />
  • 63.
  • 64.
  • 65. BRANDS<br /><ul><li>IN US , VALSARTAN IS MARKETED UNDER TRADE MARK DIOVAN.
  • 66. IN PAKISTAN ,IT IS MARKETED UNDER TRADE MARK ANGIOTAN.
  • 67. IN INDIA,IT IS MARKETED BY CIPLA UNDER TRADE MARK VALTAN AND BY TORRENT PHARMACEUTICALS UNDER NAME VALZAAR.</li></li></ul><li>
  • 68.
  • 69.
  • 70. SIDE EFFECTS OF DIOVAN<br />LEADS TO HEADACHE AND DIZZINESS.<br />SENSTIVITY TO SUNLIGHT AND BRIGHT ARTIFICIAL LIGHT.<br />THERE IS A CASE OF A STILLBIRTH IN WHICH VALSARTAN IS<br />IMPLICATED.<br />
  • 71. THANKS<br />

×